Feedback / Questions
CRB-913 - Corbus Pharma
https://www.globenewswire.com/news-release/2025/12/11/3203762/0/en/Corbus-Pharmaceuticals-Reports-Results-from-Phase-1a-Study-of-Oral-CB1-Inverse-Agonist-CRB-913-for-the-Treatment-for-Obesity-Demonstrating-Favorable-Safety-Profile-and-Emerging-Evi.html
Dec 10, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next